{"id":"dpp-iv-inhibitor","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypoglycemia"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL505629","moleculeType":"Small molecule","molecularWeight":"378.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to increased insulin secretion in response to meals and decreased glucagon secretion. The increased incretin levels also enhance the release of insulin from the pancreas in response to meals, thereby lowering blood glucose levels.","oneSentence":"DPP-IV inhibitors block the action of dipeptidyl peptidase-4, an enzyme that breaks down incretin hormones, thereby increasing incretin levels and enhancing glucose-dependent insulin secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:35:01.562Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07460336","phase":"NA","title":"Effects of Cofrogliptin on Beta-Cell Function in LADA Patients","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-15","conditions":"Latent Autoimmune Diabetes in Adults (LADA)","enrollment":84},{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT06495281","phase":"","title":"Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-10-26","conditions":"Type 2 Diabetes Mellitus","enrollment":2044},{"nctId":"NCT07439536","phase":"PHASE4","title":"Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-07-01","conditions":"Liver Cirrhosis With Diabetes","enrollment":64},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT03363464","phase":"","title":"Comparative Effectiveness of Empagliflozin in the US","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2017-10-16","conditions":"Diabetes Mellitus, Type 2","enrollment":230000},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT06263673","phase":"PHASE4","title":"Anti-Diabetic Medications to Fight PD and LBD","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-05-07","conditions":"Lewy Body Dementia, Parkinson Disease","enrollment":18},{"nctId":"NCT07365592","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT07332156","phase":"","title":"Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-01-01","conditions":"Type 2 Diabetes, COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis)","enrollment":21692},{"nctId":"NCT05313529","phase":"NA","title":"LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-10-08","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":396},{"nctId":"NCT02314637","phase":"PHASE3","title":"Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07241897","phase":"PHASE3","title":"DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-15","conditions":"Ischemic Stroke, Diabete Mellitus","enrollment":312},{"nctId":"NCT05768945","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-30","conditions":"Diabetes","enrollment":742670},{"nctId":"NCT05214573","phase":"","title":"Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-12-01","conditions":"Type 2 Diabetes, Cardiac Disease","enrollment":386301},{"nctId":"NCT07198191","phase":"","title":"SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2014-09-01","conditions":"Acute Myocardial Infarction (AMI), Type 2 Diabetes Mellitus (T2DM)","enrollment":200000},{"nctId":"NCT07108985","phase":"PHASE4","title":"Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-09","conditions":"Diabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance","enrollment":100},{"nctId":"NCT07073768","phase":"PHASE3","title":"Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Khyber Medical College, Peshawar","startDate":"2025-07-01","conditions":"Diabetes Mellitus Type 2, Glycemic Control for Diabetes Mellitus","enrollment":126},{"nctId":"NCT04735042","phase":"","title":"SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2020-10-07","conditions":"Type 2 Diabetes, Urinary Tract Infections","enrollment":60},{"nctId":"NCT04410341","phase":"PHASE1, PHASE2","title":"The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-05-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":106},{"nctId":"NCT04171219","phase":"PHASE2","title":"Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-19","conditions":"Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":31},{"nctId":"NCT03464045","phase":"","title":"Empa PASS on Urinary Tract Malignancies","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":344995},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT06838286","phase":"","title":"Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes","status":"RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-03-16","conditions":"Diabetes Mellitus, Type 2","enrollment":10000},{"nctId":"NCT02737657","phase":"","title":"An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2016-04","conditions":"Diabetes Mellitus, Type 2","enrollment":379},{"nctId":"NCT03793023","phase":"","title":"Observational Study to Evaluate the Efficacy and Safety of Teneligliptin","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2016-01-05","conditions":"Type 2 Diabetes Mellitus","enrollment":2983},{"nctId":"NCT06770894","phase":"PHASE3","title":"DPP4-Inhibitors and Bone Metabolism in Diabetes","status":"COMPLETED","sponsor":"Azienda Policlinico Umberto I","startDate":"2019-09-24","conditions":"Osteoporosis, Bone Loss, Postmenopausal, Diabetes Mellitus Type 2","enrollment":132},{"nctId":"NCT04727580","phase":"PHASE2","title":"HSK7653 in Chinese Patients with Impaired Glucose Tolerance","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2021-03-29","conditions":"Impaired Glucose Tolerance","enrollment":99},{"nctId":"NCT06703268","phase":"PHASE2","title":"A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-01-15","conditions":"Type 2 Diabetes","enrollment":64},{"nctId":"NCT03717194","phase":"PHASE3","title":"Effect of Ertugliflozin on Cardiac Function in Diabetes","status":"COMPLETED","sponsor":"Soo Lim","startDate":"2019-06-01","conditions":"Type2 Diabetes, Heart Failure","enrollment":102},{"nctId":"NCT02864914","phase":"","title":"Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-03-15","conditions":"Diabetes Mellitus, Type 2","enrollment":333580},{"nctId":"NCT06611904","phase":"NA","title":"The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Attikon Hospital","startDate":"2018-02-01","conditions":"Urine Albumin (UAlb), Glycocalyx, Arterial Stiffness","enrollment":60},{"nctId":"NCT03817463","phase":"","title":"A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-04-15","conditions":"Diabetes Mellitus, Type 2","enrollment":327624},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT03939624","phase":"","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Type2 Diabetes, Myocardial Infarction, Ischemic Stroke","enrollment":419734},{"nctId":"NCT06099067","phase":"","title":"Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-05-15","conditions":"Type 2 Diabetes Mellitus","enrollment":239990},{"nctId":"NCT04295005","phase":"","title":"A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":24500},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT02285985","phase":"PHASE4","title":"Effects of Saxagliptin on Adipose Tissue Inflammation in Humans","status":"COMPLETED","sponsor":"Phoenix VA Health Care System","startDate":"2013-02","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":103},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT06145360","phase":"PHASE4","title":"Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient","status":"COMPLETED","sponsor":"SINA Health Education and Welfare Trust","startDate":"2023-12-01","conditions":"Glucose Metabolism Disorders, Diabetes Mellitus, Type 2, Hypoglycemic Agents","enrollment":150},{"nctId":"NCT06348706","phase":"PHASE3","title":"Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-11-10","conditions":"Diabetes Mellitus, Type 1, NASH","enrollment":60},{"nctId":"NCT05818995","phase":"","title":"Therapeutic Drug Use for CKD Patients","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2022-07-01","conditions":"Chronic Kidney Disease","enrollment":10000},{"nctId":"NCT06301191","phase":"","title":"The Effect of Semaglutide on Cardiovascular Markers and Liver Function","status":"RECRUITING","sponsor":"Attikon Hospital","startDate":"2022-03-01","conditions":"Diabetes Type 2","enrollment":50},{"nctId":"NCT06218342","phase":"PHASE4","title":"Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-02-15","conditions":"Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":156},{"nctId":"NCT03231709","phase":"PHASE4","title":"Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-08-18","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT03014479","phase":"PHASE4","title":"Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-18","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT06164535","phase":"PHASE4","title":"The Effects of DPPIs on Cognitive Function of Diabetic Patients","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-12-30","conditions":"Cognitive Impairment","enrollment":105},{"nctId":"NCT03807440","phase":"","title":"DIA_CENTRAL:T2D Treatment Pattern in Central Europe","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-08-26","conditions":"Diabetes Mellitus, Type 2","enrollment":4083},{"nctId":"NCT06148259","phase":"NA","title":"SGLT Inhibitors Versus DDP4 Inhibitors and Prostate in Patient With Diabetes","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2021-03-12","conditions":"Diabetes Mellitus, Prostatic Hyperplasia","enrollment":57},{"nctId":"NCT05977465","phase":"PHASE1, PHASE2","title":"Empagliflozin in Treatment of Peripheral Diabetic Neuropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-01-20","conditions":"Diabetic Neuropathy Peripheral","enrollment":50},{"nctId":"NCT03921242","phase":"","title":"Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2019-08-01","conditions":"Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic","enrollment":4888},{"nctId":"NCT06021119","phase":"PHASE3","title":"Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop System","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-03-23","conditions":"Time in Range","enrollment":50},{"nctId":"NCT06010992","phase":"PHASE2","title":"Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT03877406","phase":"PHASE4","title":"Effect of Empagliflozin on Body Composition and Ketones","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-08-01","conditions":"Diabetes Mellitus, Fat; Intolerance, Pancreas","enrollment":200},{"nctId":"NCT03936049","phase":"","title":"Replication of the LEADER Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-22","conditions":"Diabetes","enrollment":168690},{"nctId":"NCT04215523","phase":"","title":"Replication of the DECLARE Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-07-08","conditions":"Diabetes","enrollment":49790},{"nctId":"NCT04215536","phase":"","title":"Replication of the EMPAREG Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-07-08","conditions":"Diabetes","enrollment":103752},{"nctId":"NCT03936010","phase":"","title":"Replication of the CANVAS Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-22","conditions":"Diabetes","enrollment":152202},{"nctId":"NCT05870462","phase":"PHASE4","title":"Semaglutide and Vascular Regeneration","status":"UNKNOWN","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2023-04-29","conditions":"Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT05817097","phase":"","title":"Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2023-08","conditions":"Cerebral Infarction, Infarction, Brain, Dipeptidyl-Peptidase IV Inhibitors","enrollment":22119},{"nctId":"NCT05902468","phase":"PHASE2, PHASE3","title":"Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-06-28","conditions":"Diabetes Mellitus, Type 2","enrollment":88},{"nctId":"NCT02029846","phase":"PHASE4","title":"Glycemia in Diabetic Elders Trial","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":2},{"nctId":"NCT04419337","phase":"PHASE2","title":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Stroke","enrollment":200},{"nctId":"NCT03871621","phase":"PHASE4","title":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT05663736","phase":"PHASE4","title":"Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2020-01-01","conditions":"Ejection Fraction","enrollment":80},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT04825795","phase":"","title":"DPP4 Inhibitor and Coronary Atherosclerosis in Patients Receiving Insulin Therapy","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2010-01-01","conditions":"Diabetes Mellitus","enrollment":4007},{"nctId":"NCT05578352","phase":"NA","title":"The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT04161430","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-01-02","conditions":"Type 2 Diabetes Mellitus","enrollment":766},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03748810","phase":"","title":"Head-to-head Comparison of Empagliflozin and Dapagliflozin","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2016-01-01","conditions":"Type2 Diabetes","enrollment":600},{"nctId":"NCT05266404","phase":"PHASE1","title":"Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-21","conditions":"Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)","enrollment":46},{"nctId":"NCT05429554","phase":"","title":"The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"MTI University","startDate":"2022-06","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT02041234","phase":"PHASE4","title":"Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2014-02","conditions":"Type II Diabetes in Subjects BMI 27 to 32","enrollment":40},{"nctId":"NCT05162690","phase":"PHASE2, PHASE3","title":"Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-05-01","conditions":"Diabetic Peripheral Neuropathy","enrollment":40},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT03486964","phase":"","title":"Use of Incretins in Diabetic Patients","status":"COMPLETED","sponsor":"University of Pavia","startDate":"2018-03-27","conditions":"Diabetes Mellitus, Type 2","enrollment":2234},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT05359341","phase":"NA","title":"Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2020-09-20","conditions":"Diabete Type 2","enrollment":175},{"nctId":"NCT05353673","phase":"PHASE2","title":"The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2021-06-01","conditions":"Immune Thrombocytopenia, Blood Coagulation Disorders, Thrombocytopenia","enrollment":120},{"nctId":"NCT05290506","phase":"PHASE3","title":"Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2020-08-01","conditions":"PreDiabetes, Type 2 Diabetes","enrollment":50},{"nctId":"NCT04976283","phase":"PHASE4","title":"Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver","status":"UNKNOWN","sponsor":"Getz Pharma","startDate":"2021-09-15","conditions":"Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD","enrollment":123},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT04283318","phase":"NA","title":"Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2018-06-13","conditions":"Healthy, Obesity, Type 2 Diabetes Mellitus","enrollment":80},{"nctId":"NCT03764631","phase":"","title":"Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-09-26","conditions":"Diabetes Mellitus, Type 2","enrollment":1502},{"nctId":"NCT03770052","phase":"PHASE4","title":"Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2018-10-24","conditions":"Type 2 Diabetes Mellitus, Inadequate Glucose Control","enrollment":159}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":403,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DPP-IV Inhibitor","genericName":"DPP-IV Inhibitor","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DPP-IV inhibitors block the action of dipeptidyl peptidase-4, an enzyme that breaks down incretin hormones, thereby increasing incretin levels and enhancing glucose-dependent insulin secretion. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}